Quibim, a global leader in quantitative medical imaging solutions, today announced that its flagship solution, QP-Prostate, has been selected for a major NHS-backed rollout aimed at improving early detection of prostate cancer across seven hospitals in England.
Prostate cancer is the most common cancer in men in the UK, with over 52,000 new cases and 12,000 deaths each year. Despite advances in care, only half of all cases are diagnosed early – when treatment is most effective. The NHS Long Term Plan aims to raise this to 75% by 2028.
QP-Prostate, Quibim’s AI-based software, supports radiologists by automatically identifying suspicious areas in prostate MRI scans. Early clinical data shows it can help detect 10.6% more early-stage prostate cancers, potentially saving lives and reducing the burden on the healthcare system.
Dr. Ángel Alberich-Bayarri, CEO of Quibim comments: “This NHS rollout is a major milestone in our mission to improve cancer diagnostics through AI. We’re proud to support the NHS in advancing early detection and addressing health inequalities in prostate cancer care. By empowering radiologists with AI, we can help ensure more men are diagnosed earlier, when their chances of survival are highest.”
The two-year project will involve over 3,000 patients across a geographically diverse group of hospitals and will assess:
- Increases in prostate cancer diagnoses and early-stage detection.
- Cost-effectiveness and long-term impact on NHS resources.
- The role of AI in reducing diagnostic disparities, particularly among Black men, who face double the risk of developing prostate cancer and a 30% higher mortality rate.
- The project will also include public and patient engagement to explore perceptions of AI in healthcare and ensure ethical, transparent deployment.
David Bazaga, VP of Product at Quibim adds: “QP-Prostate was designed to seamlessly integrate into radiology workflows and deliver real clinical value. This opportunity will allow us to demonstrate how AI can enhance diagnostic confidence, reduce variability, and support more equitable access to high-quality prostate cancer care.”
This rollout has been possible thanks to the Small Business Research Initiative (SBRI), that allows the NHS to access innovative companies with mature technologies. Through supporting the deployment of mature technologies in healthcare, SBRI allows companies to demonstrate real world evidence of benefits to accelerate their adoption in daily practice.
This work was commissioned and funded by the NHS Cancer Programme, with the support of SBRI Healthcare and the Accelerated Access Collaborative. The views expressed in the publication are those of the author(s) and not necessarily those of the NHS Cancer Programme or its stakeholders.